News

New genetic variants that may affect a person’s risk for developing Alzheimer’s disease have now been identified as part of the national Alzheimer’s Disease Sequencing Project (ADSP). These findings “will provide insight into disease mechanisms and targets for biological experiments to gain further understanding about the role of these…

Iron dysregulation in the brains of patients with early onset of Alzheimer’s disease (EOfAD) plays a central role in disease development and progression, according to a new theory. The study, “Dysregulation of Neuronal Iron Homeostasis as an Alternative Unifying Effect of Mutations Causing Familial Alzheimer’s Disease,” was published in…

The National Institute on Aging Genetics of Alzheimer’s Disease Data Storage Site (NIAGADS), the largest genetic database on Alzheimer’s disease, will soon begin to make large sets of DNA sequences available to researchers. Analysis of these large sets of genomic data may help identify genetic risks and protective factors…

Approved medication memantine could be used as a preventive treatment to help stop or delay Alzheimer’s disease progression in people at risk, a University of Virginia study suggests. Memantine, which is already approved by the U.S. Food and Drug Administration and marketed as Namenda by Allergan, is…

Researchers have identified two biomarkers that could help determine which Alzheimer’s disease patients can benefit from Anavex 2-73 treatment. The results were reported at the 2018 Alzheimer’s Association International Conference (AAIC) in Chicago. The study, “Systematic Processing of Full Genomic Analysis of ANAVEX®2-73 Phase 2a Alzheimer’s…

Two recent studies highlight the relationship between age and dementia, one finding that people with dementia survive an average of six years after their diagnosis, regardless of how old they are, and another reporting that the prevalence of dementia increases with age, even in the oldest population. Data from…

Neurotrope’s investigational compound Bryostatin-1 showed evidence of sustained improvement in cognition compared to placebo in patients with moderate-to-severe Alzheimer’s disease, according to additional results from a Phase 2 clinical trial. This beneficial effect was sustained for at least four weeks upon ending treatment and was even more pronounced in…

Biohaven Pharmaceuticals has enrolled the first patient in its Phase 2/3 clinical trial investigating the potential of trigriluzole as a treatment for patients with mild to moderate Alzheimer’s disease. The study, which is currently recruiting, is being conducted in collaboration with the Alzheimer’s Disease Cooperative Study (ADCS)…

The latest clinical data from Genentech on crenezumab and gantenerumab demonstrate the investigational therapies’ potential to reduce amyloid aggregates in Alzheimer’s disease patients. Trial results were discussed in several presentations at the 2018 Alzheimer’s Association International Conference (AAIC), recently held in Chicago. “The range of data that…

Intensive efforts to lower blood pressure — dropping systolic blood pressure, particularly, to lower-than-recommended levels — can reduce a person’s risk of the mild cognitive impairment that may precede Alzheimer’s and of dementia, results of clinical trial show. “This is the first randomized clinical trial to demonstrate a reduction in…